GlassScriptPhysician profile
Raja B Naidu
NPI 1124095161
$24,682.61
in general payments reported to CMS, 2019-2025
41 companies · $3,880 in 2025
The $3,880 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,328 · 2020: $940 · 2021: $3,727 · 2022: $3,048 · 2023: $5,890 · 2024: $3,870 · 2025: $3,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,521 · Travel and Lodging: $6,100 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,520.67 |
| Travel and Lodging | $6,099.62 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,514.08 | 2021-2025 | Azure Xt Dr Mri Surescan, Micra, Crome Dr Mri Surescan |
| Penumbra, INC. | $4,873.20 | 2022-2024 | Indigo System, Ruby Coil |
| Abiomed | $3,239.92 | 2019-2025 | Impella |
| Abbott Laboratories | $3,203.28 | 2019-2025 | Aveir, Ultreon, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $1,562.72 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $799.71 | 2024-2025 | General - Vascular Access, Avvigo Guidance System, General - Balloon Catheters |
| Boehringer Ingelheim Pharmaceuticals, INC. | $751.08 | 2019-2025 | Jardiance |
| Amgen INC. | $590.91 | 2019-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $580.46 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $548.90 | 2019-2020 | |
| Edwards Lifesciences Corporation | $486.49 | 2021-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $335.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $305.89 | 2021-2024 | Verquvo, Belsomra |
| Sanofi-Aventis U.S. LLC | $184.23 | 2019-2020 | |
| Pfizer INC. | $183.13 | 2019-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $148.82 | 2024 | (Br5) Peripheral Ivus |
| Janssen Pharmaceuticals, INC | $145.17 | 2019-2020 | |
| Lilly USA, LLC | $136.04 | 2019-2023 | Mounjaro |
| Heartflow, INC. | $127.96 | 2023 | Ffrct |
| Insulet Corporation | $114.99 | 2025 | Omnipod |
| Amarin Pharma, INC. | $102.27 | 2019-2022 | |
| Artivion, INC. | $101.60 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.74 | 2019-2023 | Lifevest |
| Chiesi USA, INC. | $67.51 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.64 | 2021-2025 | |
| Biotronik Nro, INC. | $56.13 | 2024 | Prospera |
| Eisai INC. | $53.76 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $49.36 | 2024 | |
| Novo Nordisk INC | $46.35 | 2025 | Wegovy |
| Ge Healthcare | $38.74 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $26.33 | 2023 | Arcalyst |
| Cordis US Corp. | $24.30 | 2023 | Zephyr |
| Innovation Technologies INC | $24.15 | 2023 | Irrisept |
| Esperion Therapeutics, INC. | $22.66 | 2020 | |
| Medicomp INC | $18.57 | 2023 | Telepatch Cardiac Monitor |
| Mylan Specialty L.P. | $17.07 | 2021 | |
| Cvrx, INC. | $15.54 | 2025 | Barostim Neo System |
| Shire North American Group INC | $14.64 | 2019 | |
| Teleflex LLC | $13.70 | 2025 | Guideliner |
| Vivaquant INC, Dba Rhythm Express | $13.28 | 2025 | Rhythm Express |
| E.R. Squibb & Sons, L.L.C. | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raja Naidu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.